Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom, Inc. (DXCM) is positioned for growth due to the expanding continuous glucose monitoring (CGM) market, strong first-quarter 2026 performance, and a robust international presence. Key drivers include the expansion into the type 2 non-insulin diabetes population, the successful launch of the G7 15-Day system, and significant growth in international markets. However, the company faces risks such as uncertain CMS reimbursement decisions, rising input costs, and potential moderation of U.S. CGM market growth.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom (DXCM) is well-positioned for growth due to the expanding continuous glucose monitoring (CGM) market, strong Q1 2026 performance, and robust international presence. Despite competitive risks and potential delays in CMS reimbursement, the company's G7 15-Day launch and international market strategies are expected to drive customer retention and market share gains. Analysts predict continued positive earnings and revenue trends for DexCom in the coming quarters.
Insulet launches Omnipod 5 insulin system in Spain
Insulet Corporation has commercially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making Spain the 20th country where Omnipod 5 is available. The system is designed for individuals aged two and older with type 1 diabetes and is compatible with Abbott’s FreeStyle Libre 2 Plus and Dexcom’s G7 sensors. Insulet is also working with Spanish health authorities to ensure market access while continuing its aggressive international expansion.
Insulet launches Omnipod 5 insulin system in Spain By Investing.com
Insulet Corporation has officially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making it the 20th country for Omnipod 5 and 26th market overall for Insulet's Omnipod products. This expansion targets Spain's 189,000 individuals with type 1 diabetes, enabling automated insulin delivery and data management for better diabetes care. Despite the aggressive international growth and 32% revenue increase, InvestingPro analysis suggests the stock is currently overvalued, while the company also faces recent product recall concerns and new analyst coverage.
Insulet launches Omnipod 5 and Omnipod Discover in Spain
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking its availability in the 26th country overall and 20th for Omnipod 5. The Omnipod 5 system is designed for type 1 diabetes patients aged two and older, automatically adjusting insulin delivery and being compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 CGMs. Omnipod Discover is a web-based platform for data analytics aimed at improving therapy discussions.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (DXCM) breached their fiduciary duties to shareholders. Long-term shareholders of DexCom are encouraged to contact the firm to explore options such as corporate governance reforms, return of funds to the company, or other relief. The firm emphasizes that shareholder involvement can improve company policies and enhance shareholder value.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages DexCom shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial recovery. Shareholder involvement is highlighted as crucial for improving company policies and enhancing shareholder value.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss legal options, including corporate governance reforms, return of funds, or financial incentives. Shareholder involvement is highlighted as crucial for improving company policies and enhancing shareholder value.
TNDM - Tandem Diabetes Care Inc Options
This article provides a detailed financial overview of Tandem Diabetes Care Inc. (TNDM), including its last closing price, market capitalization, key financial ratios, earnings per share, sales performance, and insider/institutional ownership. It also presents various performance metrics across different timeframes and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
Global X HealthTech ETF (HEAL) ETF Holders - Institutional Ownership
This article provides details about the Global X HealthTech ETF (HEAL), including its current stock price, PE and PB ratios, volume, dividend yield, and top holdings. It notes that institutional ownership data and guru trades are not available without a premium membership. The page also offers investment tools and educational resources from GuruFocus.
DexCom Inc (DXCM) Stock Up 3.5% and Still Undervalued -- GF Scor
DexCom Inc (DXCM) shares rose 3.5% to $71.25 and are currently classified as significantly undervalued according to GuruFocus's GF Value™ of $103.81, offering a 31.4% margin of safety. The company boasts a strong GF Score™ of 90/100, driven by excellent financial strength (8/10) and growth (10/10), despite a lower valuation rank (4/10) suggesting undervaluation. However, insider selling totaling $3.3 million over the past three months, with no buying activity, introduces a cautionary note for investors.
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of DexCom Inc. (DXCM) rose 3.47% to $71.25 on Thursday. Despite this daily gain, the stock underperformed compared to its competitors, even as the S&P 500 Index remained mostly unchanged and the Dow Jones Industrial Average saw a 1.14% increase. This marks the second consecutive day of gains for DexCom Inc.
NTCT - Netscout Systems Inc Volatility & Greeks
This article provides a detailed financial overview of Netscout Systems Inc. (NTCT), including its stock performance, key financial ratios, and volatility metrics. It covers aspects from market capitalization and income to insider transactions and analyst recommendations. The data indicates recent stock price changes, historical performance, and various valuation multiples.
DexCom Inc. stock outperforms competitors on strong trading day
Shares of DexCom Inc. (DXCM) increased by 2.24% to $68.86 on Wednesday, despite a general downturn in the stock market where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This rise ended a two-day losing streak for DexCom. The company's stock outperformed its competitors during an overall poor trading session.
PODD - Insulet Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Insulet Corp (PODD). It details key financial metrics, stock performance, analyst recommendations, and insider transaction information, offering a snapshot of the company's current market standing.
DXCM - Dexcom Inc Latest SEC Filings
This article provides the latest SEC filings information and comprehensive financial data for Dexcom Inc (DXCM). It details the company's recent stock performance, key financial metrics such as market cap, income, sales, P/E ratio, and growth rates. The information also includes insider and institutional ownership, profitability margins, and analyst recommendations.
TNDM - Tandem Diabetes Care Inc Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Tandem Diabetes Care Inc. (TNDM). It highlights key figures such as the last closing price, market capitalization, income, sales, various financial ratios, and stock performance over different periods. The data indicates recent stock movement, insider and institutional ownership, and profitability margins.
DexCom Inc. stock underperforms Tuesday when compared to competitors
Shares of DexCom Inc. (DXCM) fell by 3.76% on Tuesday, closing at $67.35, despite a generally positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, making this DexCom's second consecutive day of losses.
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM
This article focuses on the enterprise value to EBITDA forward metric for DexCom, Inc. (SIX:DXCM). It indicates that the data is presented without specific numerical values but highlights that the information is derived from financial reports within the TradingView platform.
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM) - Recover Losses - Contact Levi & Korsinsky Before December 26, 2025
A securities class action lawsuit has been filed against DexCom, Inc. (DXCM) on behalf of investors who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly concealed. Investors are encouraged to contact Levi & Korsinsky, LLP before December 26, 2025, to explore potential recovery.
Price to sales forward of DexCom, Inc. – SIX:DXCM
This article provides financial information for DexCom, Inc. (SIX:DXCM), specifically focusing on its price-to-sales forward ratio. It appears to be a stub or a data point from a larger financial platform like TradingView, with details on market and reference data providers. The content highlights the stock's listing on the SIX Swiss Exchange and offers various navigational links related to markets, products, and community features of the financial platform.
Price to book forward of DexCom, Inc. – NASDAQ:DXCM
This article provides financial information for DexCom, Inc. (NASDAQ: DXCM), specifically focusing on its "Price to book forward" metric. It appears to be a stub or a section of a larger financial data page, showing navigation and copyright information for financial data providers like ICE Data Services and FactSet.
Price to earnings forward of DexCom, Inc. – NASDAQ:DXCM
This article provides financial data for DexCom, Inc. (NASDAQ: DXCM), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering an overview of the company's financials for investors. The information includes standard market data and copyright acknowledgments.
Price to earnings forward of DexCom, Inc. – SIX:DXCM
This article displays the "Price to earnings forward" metric for DexCom, Inc. (SIX:DXCM). It indicates that there is no specific value available for this period, implying the data might be pending or not currently provided within the displayed section. The page is primarily a financial data interface from TradingView.
Enterprise value to revenue forward of DexCom, Inc. – SIX:DXCM
This article provides a brief financial update for DexCom, Inc. (SIX:DXCM), specifically focusing on its enterprise value to revenue forward metric. It indicates that the market for DXCM on the SIX Swiss Exchange is currently closed with no trades. The article is part of a larger financial data and analysis platform.
Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky Before December 26, 2025 to Join Class Action
Levi & Korsinsky, LLP has announced a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly downplayed. Investors are encouraged to contact the firm before December 26, 2025, to explore potential recovery.
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All
DexCom, Inc. (DXCM) announced FDA clearance for expanded use of its Stelo Glucose Biosensor, now including children aged 2 and older who do not use insulin. This move aims to broaden access to glucose biosensing and preventive care through a redesigned Stelo app, set to roll out in the U.S. in July and internationally starting later this year. The company emphasizes the growing prevalence of Type 2 diabetes in young people and the new ability for non-insulin users to track blood sugar without a prescription.
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025
Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made material design changes to its glucose monitoring products (G6 and G7) without FDA authorization, rendering them less reliable and posing health risks, which the company allegedly concealed. Investors who suffered losses are urged to contact Levi & Korsinsky before December 26, 2025, to explore potential recovery options.
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors - Lead Plaintiff Deadline December 26, 2025
Levi & Korsinsky, LLP has announced a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, while the company overstated their enhancements and downplayed issues. Investors who suffered losses are encouraged to contact the firm by the lead plaintiff deadline of December 26, 2025.
Join Class Action to Recover Losses from DexCom, Inc. (DXCM) - Contact Levi & Korsinsky Before December 26, 2025
Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims DexCom made unauthorized material design changes to its glucose monitoring products (G6 and G7) which rendered them less reliable and posed health risks, and that the company made false and misleading statements about the G7's enhancements and reliability. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to contact Levi & Korsinsky to learn about their rights before December 26, 2025.
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made material design changes to its glucose monitoring products, the G6 and G7, without FDA authorization, rendering them less reliable and potentially posing health risks, leading to overstated enhancements and downplayed issues. Investors have until December 26, 2025, to learn about their rights to potentially recover losses.
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All
DexCom, Inc. (DXCM) announced FDA clearance for its Stelo Glucose Biosensor for children aged 2 and older who do not use insulin, expanding its use beyond adults. The company plans to roll out a redesigned Stelo app in America in July for enhanced glucose insights and will launch Stelo in several other countries later this year and into 2027. This initiative aims to broaden access to glucose biosensing and provide preventive, customized care, especially as Type 2 diabetes increases among young people.
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM)
Levi & Korsinsky, LLP has initiated a securities class action lawsuit against DexCom, Inc. (DXCM) on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, and that the company made false and misleading public statements. Investors who purchased DexCom securities during this period are encouraged to learn about their rights to potentially recover losses.
Bernstein Says Life Science Sector is Improving, Resumes Thermo Fisher Scientific (TMO) Coverage
Bernstein has resumed coverage of Thermo Fisher Scientific (TMO) with a Market Perform rating and a $520 price target, citing an improving life science tools and diagnostics sector due to new drug approvals, increased funding, and AI-driven demand. This follows Piper Sandler's earlier Neutral rating with a $510 price target, which suggests waiting for clearer growth drivers in the sector. Thermo Fisher Scientific specializes in advancing life sciences research and supporting patient health through various scientific solutions.
Union Bancaire Privee UBP SA Has $35.83 Million Holdings in RTX Corporation $RTX
Union Bancaire Privee UBP SA reduced its stake in RTX Corporation by 10.5% in the first quarter, yet still maintains significant holdings valued at $35.83 million. RTX continues to garner a "Moderate Buy" consensus from analysts, supported by strong fundamentals including increased earnings, revenue, a boosted quarterly dividend, and a large U.S. Navy missile contract. The article also details other institutional investor activity and recent analyst upgrades for RTX.
Ensysce initiates final stage of opioid overdose protection study
Ensysce Biosciences (NASDAQ:ENSC) has begun the final stage of its PF614-MPAR-102 clinical study, evaluating its MPAR technology designed to prevent oral opioid overdose. Despite the stock's significant decline over the past year and a warning from Nasdaq regarding minimum stockholders' equity, the company is also looking to expand MPAR's use to other conditions and recently secured a patent in Taiwan. InvestingPro analysis suggests the stock is undervalued, but also highlights the company's rapid cash burn.
DexCom, Inc. Actuals & Estimates (NASDAQ:DXCM)
This article provides financial actuals and estimates for DexCom, Inc. (NASDAQ:DXCM), including income statement, balance sheet, cash flow, and valuation metrics. It also covers analyst forecasts, historical price data, volatility, market capitalization, and upcoming earnings reports for the company.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) shares rose 2.17% to $70.14 on Friday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average fall. The stock closed 22.05% below its 52-week high of $89.98.
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries
DexCom (DXCM) is launching a redesigned Stelo app, expanding its reach into four new international markets: the UK, Australia, New Zealand, and South Korea, following recent FDA clearance for over-the-counter pediatric use in the U.S. This strategic move aims to broaden its user base beyond intensive insulin users to include prediabetes and early type 2 individuals, enhancing recurring revenue potential through consumer-style digital health tools. Investors are keenly watching how effectively DexCom converts these new markets and product updates into sustained user adoption and financial growth, while also considering competition and regulatory challenges.
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
This article compares Abbott (ABT) and DexCom (DXCM), two leading companies in the continuous glucose monitoring (CGM) market, to determine which offers a better investment opportunity. While Abbott faces challenges like dilution from an acquisition and volatility in diagnostics, DexCom benefits from strong CGM demand, new product launches, and expanding insurance coverage. The analysis suggests that DexCom, despite trading at a premium, currently presents a more compelling growth prospect.
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Dexcom Inc (DXCM), focusing on its current price momentum, support and resistance levels, and key technical indicators. It notes that DXCM's price momentum score is 6.08 and highlights that the stock is trading between resistance at $75.52 and support at $65.16. The analysis also summarizes various indicators and moving averages, providing "Sell," "Neutral," and "Buy" signals.
Dexcom Inc (DXCM) Institutional Confidence
Dexcom Inc (DXCM) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This reflects a high level of confidence from institutional investors, with 99.64% institutional ownership, though this marks a slight quarter-over-quarter decrease. The largest institutional shareholder is ETHSX, which significantly increased its holdings.
What Should Investors Expect from Verisk's Q1 2026 Earnings
Verisk (VRSK) is set to report its Q1 2026 earnings on April 29, with analysts projecting $1.77 EPS on $773.5 million in revenue, following a strong beat in Q4 2025. The company's competitive edge stems from its proprietary data, AI-driven solutions, and deep integration into the insurance sector, driving recurring revenue and margin expansion. Investors should monitor insurance industry pricing pressures and the recent stock shelf registration while considering the company's robust growth targets and capital allocation strategies.
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Dexcom Inc (DXCM), noting its current score of 6.55 within the Healthcare Equipment & Supplies industry. Key metrics like a beta of 1.44, indicating higher volatility than the S&P 500, and various return and drawdown figures are presented. The report also details different volatility, liquidity, and risk-adjusted return measures for DXCM.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) stock saw a strong trading day, rising 1.40% to $121.25, outperforming its competitors. The stock closed $125.75 below its 52-week high of $247.00, achieved on November 8, 2024. Its trading volume was 1.6 million shares, slightly below its average of 2.1 million shares.
DexCom Inc. stock underperforms Thursday when compared to competitors
DexCom Inc. (DXCM) stock fell 1.58% to $68.65 on Thursday, underperforming the broader market. This drop occurred during a mixed trading session where the Dow Jones Industrial Average rose, while the S&P 500 Index saw a slight decline. The company's stock is now 23.71% below its 52-week high.
Abbott Laboratories Stock (ABT) Moved Up by 3.12% on Jun 25: A Full Analysis
Abbott Laboratories (ABT) stock increased by 3.12% due to strategic initiatives, strong analyst support, and its status as a dividend aristocrat. Key drivers include a partnership with ALZpath for a blood-based Alzheimer's test and strong performance in its FreeStyle Libre continuous glucose monitoring platform. Despite some company-specific risks like the Exact Sciences acquisition and competition in CGM, analysts maintain bullish ratings, anticipating positive Q2 earnings.
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
Abbott Laboratories (ABT) shares have dropped significantly, but the company is considered a strong buy due to its FreeStyle Libre continuous glucose monitor (CGM) and its potential expansion into the Type 2 basal-insulin market. Despite competition and integration costs from an acquisition, analysts are largely bullish, citing the company's strong dividend and attractive forward P/E ratio. The next CGM earnings report on July 20, 2026, is a key event to watch for further confirmation of growth.
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
Abbott Laboratories (ABT) has seen its stock drop due to sector-wide compression, but its diabetes franchise and medical devices unit show strong growth. The FreeStyle Libre's expansion into the Type 2 basal-insulin market, supported by positive clinical trial data, is a significant catalyst. Despite competition and integration costs from a recent acquisition, analysts maintain a "Buy" rating, citing a low forward P/E and asymmetric risk/reward at its current price.
DexCom, Inc. Actuals & Estimates (SIX:DXCM.USD)
This article provides an overview of DexCom, Inc. (DXCM.USD) stock, including analyst forecasts, financial performance, and key metrics. It details the company's past earnings and revenue surprises, future estimates, and states that DexCom does not pay dividends. The report also covers the company's EBITDA and employee count.
